IC
NERV icon

Ikarian Capital’s Minerva Neurosciences NERV Stock Holding History

Ikarian Capital’s Portfolio NERV Stock Details NERV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-12,938
Closed -$759K – 197
2020
Q1 		$623K Buy
12,938
+438
+4% +$26.4K 0.05% 129
2019
Q4 		$711K Buy
+12,500
New +$551K 0.12% 86

Other funds holding NERV

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Ikarian Capital's NERV Position: Q2 2020 in Review

Ikarian Capital sold out of Minerva Neurosciences (NERV) in Q2 2020, closing a stake of 12,938 shares — an estimated $759K sold.

Ikarian Capital first reported a position in NERV in Q4 2019 and held it in 2 quarters. The position peaked at $711K in Q4 2019. 80 funds tracked by Wall St. Rank hold NERV as of Q2 2020.

  • Ikarian Capital reported no remaining Minerva Neurosciences position as of Q2 2020 after selling out during the quarter.
  • Ikarian Capital sold 12,938 Minerva Neurosciences shares in Q2 2020, an estimated $759K.
  • Ikarian Capital first reported a position in Minerva Neurosciences in Q4 2019 and held it in 2 quarters.
  • Ikarian Capital's Minerva Neurosciences position peaked at $711K in Q4 2019.
  • 80 funds tracked by Wall St. Rank held Minerva Neurosciences as of Q2 2020.

Based on Ikarian Capital's 13F filing for Q2 2020, filed 14 Aug 2020.